Cholesteatoma Management and Diagnostic Techniques

Cholesteatoma is characterised by the aberrant proliferation of keratinising squamous epithelium within the middle ear and mastoid, leading to local bone erosion, hearing impairment and potential intracranial complications. Management is fundamentally surgical, with canal wall-up and canal wall-down mastoidectomy techniques tailored to disease extent, anatomical considerations and patient factors. Increasingly, reconstruction or obliteration of mastoid cavities using autologous bone or synthetic fillers enhances postoperative anatomy and reduces cavity-related morbidity. Audiological rehabilitation and long-term surveillance complement surgery, since residual or recurrent disease may be clinically occult. Diagnostic approaches centre on high-resolution computed tomography (HRCT) for surgical planning and assessment of bony erosion, coupled with magnetic resonance imaging (MRI) sequences—especially diffusion-weighted imaging (DWI)—to detect and localise residual cholesteatoma. Advanced DWI protocols, including non-echoplanar and multishot echo-planar techniques, have improved sensitivity for small lesions, permitting a shift away from routine second-look operations. Continual refinement of imaging protocols, surgical materials and obliteration strategies underpins a personalised management pathway that balances disease eradication with preservation of hearing and quality of life.

Research from Nature Portfolio

Comparative evaluation of mastoid obliteration materials in canal wall-down tympanomastoidectomy with reconstruction has revealed that 45S5 bioactive glass significantly outperforms bone allograft in early follow-up. Over an 18-month period, patients treated with bioactive glass exhibited substantially lower rates of recurrent otorrhoea and revision surgery than those receiving allograft bone. These findings highlight the potential of bioactive glass to resist resorption, maintain cavity obliteration volume and reduce the need for further interventions. While preliminary outcomes favour bioactive glass as a simple, biocompatible filler for mastoid reconstruction, ongoing prospective trials with longer follow-up are essential to establish comparative durability against other synthetic materials and to define best-practice guidelines for obliteration in cholesteatoma surgery.

Cholesteatoma Management and Diagnostic Techniques publication trend

The graph below shows the total number of articles in cholesteatoma management and diagnostic techniques across all publications each year (not limited to Nature Index journals).

Technical terms

Cholesteatoma: An abnormal, keratinising epithelial collection in the middle ear or mastoid causing bone erosion and potential complications.

Canal wall-down mastoidectomy: A surgical technique removing the posterior ear canal wall to eradicate disease and create a single cavity combining mastoid and middle ear spaces.

Canal wall-up mastoidectomy: A more conservative mastoidectomy preserving the posterior ear canal wall to maintain native anatomy but with higher residual disease risk.

Obliteration: The process of filling a mastoid cavity with material (autologous or synthetic) to restore anatomy and prevent post-surgical morbidity.

Computed tomography (CT): A high-resolution X-ray imaging modality used to visualise bone architecture and plan surgical approaches.

Diffusion-weighted imaging (DWI): An MRI technique sensitive to water diffusion differences, deployed to detect and localise residual or recurrent cholesteatoma.

Non-echoplanar imaging (non-EPI): A DWI acquisition method reducing susceptibility artefacts and improving specificity for small cholesteatoma detection.

Bioactive glass (45S5): A synthetic, biocompatible material used for mastoid cavity obliteration, promoting osteointegration and long-term volume stability.

References

1. Allograft bone vs. bioactive glass in rehabilitation of canal wall-down surgery. Scientific Reports (2023).
2. Temporal bone CT-based anatomical parameters associated with the development of cholesteatoma. La radiologia medica (2023).
3. ESR Essentials: imaging of middle ear cholesteatoma—practice recommendations by the European Society of Head and Neck Radiology. European Radiology (2024).
4. Performance of TGSE BLADE DWI compared with RESOLVE DWI in the diagnosis of cholesteatoma. BMC Medical Imaging (2020).